Tags

Type your tag names separated by a space and hit enter

Autoimmunity and anti-TNF-alpha agents.
Ann N Y Acad Sci 2005; 1051:559-69AN

Abstract

Treatment of rheumatoid arthritis (RA) patients with anti-tumor necrosis factor-alpha (anti-TNF-alpha) biologic agents has been associated with a reduction in the levels of specific autoantibodies, such as rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP), and the induction of non- organ-specific autoantibodies (antinuclear antibodies [ANAs], anti-dsDNA, and antiphospholipid antibodies [aPLs]). The mechanisms by which the blockade of anti-TNF-alpha decreases the generation of specific autoantibodies, such as anti-CCP and RF, are not yet known. However, it has been shown that these agents can downregulate the production of several inflammatory cytokines and mediators and that these anti-inflammatory effects may account for reduced autoantibody generation, particularly in the synovial compartment. Infliximab treatment leads to the induction of ANAs in 63.8% of RA patients and 49.1% of Crohn's disease (CD) patients, and anti-dsDNA antibodies in 13% of RA patients and 21.5% of CD patients, respectively. The development of ANAs and anti-dsDNA antibodies has also been described after etanercept therapy in 11% and 15% of RA patients, respectively. In the controlled trials, increases in ANA and anti-dsDNA titers were observed in 5.3% and in 12.9% of adalimumab-treated RA patients. Only limited data on the induction of aPL antibodies during TNF-alpha blocking treatment are available.

Authors+Show Affiliations

Rheumatology Unit, Department of Rheumatology, University Hospital L Sacco, Via GB Grassi 74, 20157 Milan, Italy. sarzi@tiscali.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16126996

Citation

Atzeni, Fabiola, et al. "Autoimmunity and anti-TNF-alpha Agents." Annals of the New York Academy of Sciences, vol. 1051, 2005, pp. 559-69.
Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005;1051:559-69.
Atzeni, F., Turiel, M., Capsoni, F., Doria, A., Meroni, P., & Sarzi-Puttini, P. (2005). Autoimmunity and anti-TNF-alpha agents. Annals of the New York Academy of Sciences, 1051, pp. 559-69.
Atzeni F, et al. Autoimmunity and anti-TNF-alpha Agents. Ann N Y Acad Sci. 2005;1051:559-69. PubMed PMID: 16126996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Autoimmunity and anti-TNF-alpha agents. AU - Atzeni,Fabiola, AU - Turiel,Maurizio, AU - Capsoni,Franco, AU - Doria,Andrea, AU - Meroni,Pierluigi, AU - Sarzi-Puttini,Piercarlo, PY - 2005/8/30/pubmed PY - 2006/6/27/medline PY - 2005/8/30/entrez SP - 559 EP - 69 JF - Annals of the New York Academy of Sciences JO - Ann. N. Y. Acad. Sci. VL - 1051 N2 - Treatment of rheumatoid arthritis (RA) patients with anti-tumor necrosis factor-alpha (anti-TNF-alpha) biologic agents has been associated with a reduction in the levels of specific autoantibodies, such as rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP), and the induction of non- organ-specific autoantibodies (antinuclear antibodies [ANAs], anti-dsDNA, and antiphospholipid antibodies [aPLs]). The mechanisms by which the blockade of anti-TNF-alpha decreases the generation of specific autoantibodies, such as anti-CCP and RF, are not yet known. However, it has been shown that these agents can downregulate the production of several inflammatory cytokines and mediators and that these anti-inflammatory effects may account for reduced autoantibody generation, particularly in the synovial compartment. Infliximab treatment leads to the induction of ANAs in 63.8% of RA patients and 49.1% of Crohn's disease (CD) patients, and anti-dsDNA antibodies in 13% of RA patients and 21.5% of CD patients, respectively. The development of ANAs and anti-dsDNA antibodies has also been described after etanercept therapy in 11% and 15% of RA patients, respectively. In the controlled trials, increases in ANA and anti-dsDNA titers were observed in 5.3% and in 12.9% of adalimumab-treated RA patients. Only limited data on the induction of aPL antibodies during TNF-alpha blocking treatment are available. SN - 0077-8923 UR - https://www.unboundmedicine.com/medline/citation/16126996/full_citation L2 - https://doi.org/10.1196/annals.1361.100 DB - PRIME DP - Unbound Medicine ER -